Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor

Weon Sup Shin; Jiyou Han; Rajesh Kumar; Gyung Gyu Lee; Jonathan L. Sessler; Jong-Hoon Kim; Jong Seung Kim

doi:10.1038/srep29018

Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor

Weon Sup Shin, Jiyou Han, Rajesh Kumar, Gyung Gyu Lee, Jonathan L. Sessler, Jong-Hoon Kim, Jong Seung Kim

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

We report here a tumor-targeting masked phototherapeutic agent 1 (PT-1). This system contains SN-38 - a prodrug of the topoisomerase I inhibitor irinotecan. Topoisomerase I is a vital enzyme that controls DNA topology during replication, transcription, and recombination. An elevated level of topoisomerase I is found in many carcinomas, making it an attractive target for the development of effective anticancer drugs. In addition, PT-1 contains both a photo-triggered moiety (nitrovanillin) and a cancer targeting unit (biotin). Upon light activation in cancer cells, PT-1 interferes with DNA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter alia mitochondrial apoptotic genes, death receptors, and caspase enzymes, inducing DNA damage and eventually leading to apoptosis. In vitro and in vivo studies showed significant inhibition of cancer growth and the hybrid system PT-1 thus shows promise as a programmed photo-therapeutic ("phototheranostic").

Original language	English
Article number	29018
Journal	Scientific reports
Volume	6
DOIs	https://doi.org/10.1038/srep29018
Publication status	Published - 2016 Jul 4

ASJC Scopus subject areas

General

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1038/srep29018

Fingerprint Dive into the research topics of 'Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor'. Together they form a unique fingerprint.

Cite this

@article{0a6bbb61ab174b4fa00d39f4f95d28d9,

title = "Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor",

abstract = "We report here a tumor-targeting masked phototherapeutic agent 1 (PT-1). This system contains SN-38 - a prodrug of the topoisomerase I inhibitor irinotecan. Topoisomerase I is a vital enzyme that controls DNA topology during replication, transcription, and recombination. An elevated level of topoisomerase I is found in many carcinomas, making it an attractive target for the development of effective anticancer drugs. In addition, PT-1 contains both a photo-triggered moiety (nitrovanillin) and a cancer targeting unit (biotin). Upon light activation in cancer cells, PT-1 interferes with DNA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter alia mitochondrial apoptotic genes, death receptors, and caspase enzymes, inducing DNA damage and eventually leading to apoptosis. In vitro and in vivo studies showed significant inhibition of cancer growth and the hybrid system PT-1 thus shows promise as a programmed photo-therapeutic ({"}phototheranostic{"}).",

author = "Shin, {Weon Sup} and Jiyou Han and Rajesh Kumar and Lee, {Gyung Gyu} and Sessler, {Jonathan L.} and Jong-Hoon Kim and Kim, {Jong Seung}",

note = "Funding Information: This work was supported by The Ministry of Science, ICT & Future Planning (MSIP) of National Research Foundation of Korea (No. 2009-0081566 for JSK, No. 2012M3A9C7050139 for JHK, and No. 2015R1C1A1A02036905 for JH), Korea University Grant (for JH) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2013062997). Support for the work in Austin was provided by the National Institutes of Health (grant CA 68682 to JLS).",

year = "2016",

month = jul,

day = "4",

doi = "10.1038/srep29018",

language = "English",

volume = "6",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Programmed activation of cancer cell apoptosis

T2 - A tumor-targeted phototherapeutic topoisomerase I inhibitor

AU - Shin, Weon Sup

AU - Han, Jiyou

AU - Kumar, Rajesh

AU - Lee, Gyung Gyu

AU - Sessler, Jonathan L.

AU - Kim, Jong-Hoon

AU - Kim, Jong Seung

N1 - Funding Information: This work was supported by The Ministry of Science, ICT & Future Planning (MSIP) of National Research Foundation of Korea (No. 2009-0081566 for JSK, No. 2012M3A9C7050139 for JHK, and No. 2015R1C1A1A02036905 for JH), Korea University Grant (for JH) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. 2013062997). Support for the work in Austin was provided by the National Institutes of Health (grant CA 68682 to JLS).

PY - 2016/7/4

Y1 - 2016/7/4

N2 - We report here a tumor-targeting masked phototherapeutic agent 1 (PT-1). This system contains SN-38 - a prodrug of the topoisomerase I inhibitor irinotecan. Topoisomerase I is a vital enzyme that controls DNA topology during replication, transcription, and recombination. An elevated level of topoisomerase I is found in many carcinomas, making it an attractive target for the development of effective anticancer drugs. In addition, PT-1 contains both a photo-triggered moiety (nitrovanillin) and a cancer targeting unit (biotin). Upon light activation in cancer cells, PT-1 interferes with DNA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter alia mitochondrial apoptotic genes, death receptors, and caspase enzymes, inducing DNA damage and eventually leading to apoptosis. In vitro and in vivo studies showed significant inhibition of cancer growth and the hybrid system PT-1 thus shows promise as a programmed photo-therapeutic ("phototheranostic").

AB - We report here a tumor-targeting masked phototherapeutic agent 1 (PT-1). This system contains SN-38 - a prodrug of the topoisomerase I inhibitor irinotecan. Topoisomerase I is a vital enzyme that controls DNA topology during replication, transcription, and recombination. An elevated level of topoisomerase I is found in many carcinomas, making it an attractive target for the development of effective anticancer drugs. In addition, PT-1 contains both a photo-triggered moiety (nitrovanillin) and a cancer targeting unit (biotin). Upon light activation in cancer cells, PT-1 interferes with DNA re-ligation, diminishes the expression of topoisomerase I, and enhances the expression of inter alia mitochondrial apoptotic genes, death receptors, and caspase enzymes, inducing DNA damage and eventually leading to apoptosis. In vitro and in vivo studies showed significant inhibition of cancer growth and the hybrid system PT-1 thus shows promise as a programmed photo-therapeutic ("phototheranostic").

UR - http://www.scopus.com/inward/record.url?scp=84977269769&partnerID=8YFLogxK

U2 - 10.1038/srep29018

DO - 10.1038/srep29018

M3 - Article

C2 - 27374023

AN - SCOPUS:84977269769

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 29018

ER -

Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this